BR BRBR BellRing Brands, Inc. Loading... : Bullish and Bearish Analyst Opinions

50 million US adults now use GLP‑1 drugs, increasing protein intake ~65%. Whey prices are up 50%+ YTD, and some protein manufacturers have sold out for the year. BRBR’s Premier Protein is one of the few brands that passed heavy‑metal tests, giving it a quality moat that can capture the GLP‑1‑driven demand surge. As a publicly traded pure‑play protein powder company with strong brand recognition, BRBR is poised to benefit from a structural demand shift that the market has not fully priced in. Rising whey input costs could compress margins; increased competition from cheaper alternatives (cottage cheese, plant‑based), and the GLP‑1 trend may slow or face regulatory headwinds.

Stock fell 89% from $78 to $8.44; company guided 0-2% growth vs prior 5%, EBITDA down to $320M from $450M, gross margins compressed from 35% to 22% due to Costco price pressure. Author believes the market overreacted; with market cap ~$1B and $500M remaining buyback authorization, the company could retire half the float, supporting a recovery to $25 (3x current price). Contrarian long on a fallen angel with massive buyback tailwind; bet on margin stabilization and mean reversion once price war subsides. Continued margin compression from Costco/pricing competition, further demand weakness, execution risk on buyback (if debt/cash flow issues arise).

Barbarian Capital highlights a rough earnings season for former growth darlings in staples and discretionary sectors, with PAA Research explicitly calling $BRBR a poster child for shareholder value destruction via buybacks.

The tweet reports a day of significant double-digit declines in consumer staples and discretionary stocks, including PLNT, SHAK, VITL, TPR, WHR, COKE, and BRBR, but provides no forward-looking opinion or trade thesis.

Stock down ~80% while revenue remains ~$2.3B; valuation at 8x NTM EBITDA and 1.3x NTM revenue suggests deep pessimism. If the business is not structurally broken and cyclical headwinds (whey, tariffs, competition) ease, the multiple could re-rate higher, providing upside. A contrarian value play on a de-rated staple brand with resilient distribution and revenue. Sustained whey inflation, tariff escalation, or loss of club channel shelf space could undermine the thesis.

The stock has drawn down significantly (cited as falling from ~$80 to ~$17), trading at ~9x EV/EBITDA and an 11% Free Cash Flow yield, with an 80% ROIC due to its asset-light, outsourced manufacturing model. The market has likely over-penalized the stock due to GLP-1 weight-loss drug fears or momentum selling. However, the "Premier Protein" brand has strong distribution and sticky demand (protein is essential regardless of weight loss methods), creating a dislocation between price and business quality. LONG (Deep Value). Competition from private labels (e.g., Costco/Kirkland); single-category reliance; potential impact of GLP-1s on consumption habits.